Our results could help identify patients with clinical overlapping between COVID-19 and MAS/sHLH since the literature already recommends a triple-differentiated therapeutic (corticosteroids; cyclosporine A; etoposide) approach recently added to the use of biological agents (anti-IL1B; anti-IL-6; anti-IFNγ) for severe COVID-19 patients with MAS clinical manifestations [38,39,41,42]. Here, IFNG is linked to macrophage activation syndrome.